Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...
Seven internationally recognized nephrology experts join R1's Scientific Advisory BoardStrengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results